Five biopharmaceutical companies have completed a new round of financing! (March 12th)
Recently, companies such as HeCarbon Intelligence, Dome Technology, and Gestalt Technology have collectively obtained financing, covering core tracks such as AI pharmaceuticals, brain computer interfaces, and nuclear drug research and development, with financing scales ranging from tens of millions to 150 million yuan. Enterprises focus on breakthroughs in core technologies, promote the implementation of technologies such as robot operation and non-invasive neural regulation, and assist in the domestic substitution of high-end medical products and the high-quality development of the industry.
1ć HeCarbon Intelligence has completed a new round of financing of 50 million yuan, promoting the industrialization of “physical AI scientists”
Recently, HeCarbon Intelligence, which focuses on the research and development of “physical AI scientists”, has completed a new round of financing of 50 million yuan. This round of financing is led by Yonghua Investment, with Wei Hao Chuangxin and individual investors joining in.
It is reported that the company completed its first round of financing in August 2022, led by Yunqi Venture Capital, with participation from institutional and individual investors such as Jingya Capital and Baitu Biotechnology. Both rounds of financing focused on core technology research and development and scenario implementation. Founded in 2022, HeCarbon Intelligence’s core product Talos uses a universal dual arm mobile robot as its hardware carrier, relying on self-developed sensors and proprietary VLA (vision language action) architecture to achieve autonomous operation and real-time reasoning in professional experimental scenarios. It breaks through the rigid limitations of traditional automation equipment that is “dedicated to special machines” and can adapt to various instruments without the need to modify existing laboratories, with dynamic adaptation and error recovery capabilities.
At present, Talos has completed 50 days of continuous trial operation in BeiGene Pharmaceutical Laboratory, achieving zero errors in 15 molecular purification experiments and more than 3000 physical operations. The operational level has reached the level of a senior pharmaceutical chemist with ten years of experience, and it is the first time in the industry to achieve large-scale practical verification of such robots in real pharmaceutical scenarios. Molecular purification occupies 50% of the working time of medicinal chemists, and the application of Talos can greatly release the energy of researchers and focus on creative research.
Chen Zhigang, the founder and CEO of the company, has cross-border experience in the field of Internet medicine and pharmaceuticals. His team plans to expand scenarios along the life cycle of drug development. At this stage, it focuses on small molecule purification. Later, it will promote the automation of ADME experiments and GxP compliant production, and explore multiple scenarios such as flexible production of cosmetics. This round of financing will accelerate product iteration and multi scenario implementation, help break through the limitations of traditional automation, promote the deep integration of AI with pharmaceutical, fine chemical and other fields, and improve industrial research and development efficiency.
2ć Dome Technology completes nearly 100 million yuan A+round financing, leading the development of therapeutic brain computer interface industry with TI technology
Recently, Xi’an Dome Medical Technology Co., Ltd. (referred to as “Dome Technology”) successfully completed an A+round financing of nearly 100 million yuan. This round was led by Mingxi Capital, followed by Guanggu Production Investment, and continued funding from old shareholders such as Shunwei Capital and Huafang Capital. Xingyuan Zhitong served as the exclusive financial advisor. This financing will be focused on product iteration, clinical registration promotion, business expansion, and innovative technology research and development, injecting strong momentum into the industrialization of the company’s core technology.
Dome Technology is deeply engaged in the field of non-invasive deep brain precise neural regulation, with a core focus on the research and development and transformation of time interference technology (TI). With advantages such as non-invasive, deep brain regulation, high precision, and multi-target collaboration, this technology breaks through the barriers of traditional neural regulation technology and builds a full chain technology platform covering “principle verification technology iteration clinical translation”.
At present, the company has partnered with more than 200 scientific research and medical institutions at home and abroad to promote scientific research and clinical exploration around nearly 50 indications. The market share of related equipment has reached 87%, and it has been applied in more than 10 top overseas neuroscience laboratories. GCP clinical trials for multiple indications are steadily advancing. The TI-FUSION multimodal collaborative neural regulation system proposed by it forms a product matrix that combines precision and scalability, laying a leading position in the industry.
As a future industry that is a key focus of the 15th Five Year Plan, brain computer interfaces are facing opportunities for large-scale development, and a billion dollar blue ocean market is gradually taking shape. The landing of this round of financing is not only a recognition of the technical strength and clinical potential of Dome Technology TI, but also an acceleration of the industrialization of its therapeutic brain computer interface technology, helping the company consolidate its advantages in the field of non-invasive deep brain regulation and promote the high-quality development of China’s therapeutic brain computer interface industry.
3ć Yili Pharmaceutical completes a new round of financing of nearly 100 million yuan to accelerate the research and clinical translation of innovative radiopharmaceuticals
On March 12th, Hangzhou Yili Pharmaceutical Co., Ltd. announced the completion of a new round of financing of nearly 100 million yuan, jointly invested by Longfeng Venture Capital, Yicheng Investment, Hongsheng Capital, and Beike Fund. The funds raised this time will be mainly used for molecular discovery, technology platform construction, and clinical translation of new target projects, promoting the steady entry of innovative radiopharmaceutical pipelines into the clinical stage.
Yili Pharmaceutical was founded in 2024 and is an innovative radiopharmaceutical research and development enterprise focused on the integration of diagnosis and treatment of tumors and neurological diseases. Its cumulative financing has reached 300 million yuan. The company adheres to the core concept of “innovation driven, precision medicine”, integrates molecular targeting and radionuclide technology, develops efficient and safe diagnostic and therapeutic radiopharmaceuticals, and is committed to providing precise diagnosis and treatment solutions for patients worldwide.
At present, the company’s new target project has made phased progress, completing the discovery of lead molecules and preliminary in vitro and in vivo validation. Some candidate molecules have shown excellent targeting specificity and potential for drug development. Founder Dr. Yu Feng stated that this round of financing will significantly improve the efficiency of key target research and development. The company will continue to strengthen its integrated diagnosis and treatment layout, promote innovative molecular clinical development in accordance with international standards, and provide patients with more effective treatment options.
4ć Gestalt Technology has completed a 150 million yuan angel round financing, breaking the domestic record for angel round funding of brain computer interfaces
Recently, Gestala, the first hard tech enterprise in China to focus on ultrasound brain computer interfaces, announced the completion of a 150 million yuan angel round financing, breaking the record for the highest angel round financing in the Chinese brain computer interface field. This round of financing is jointly led by Guosheng Capital and Daotong Investment, with multiple well-known investment institutions and enterprises following suit, and Huaxing Capital serving as the exclusive financial advisor.
Gestalt Technology was founded in January 2026, jointly founded by Peng Lei and Chen Tianqiao. It completed over fundraising in just two months, and its financing scale is second only to Merge Labs, which was co founded by OpenAI founders, internationally. The company focuses on the ultrasound brain computer interface route, which has core advantages such as non-invasive, whole brain “reading and writing”, and multi-target neural circuit regulation compared to traditional electrical invasive technology. It is suitable for various neurological diseases such as chronic pain and depression, and has broad clinical application prospects.
At present, the company’s first product focused on chronic pain management has completed over 30 clinical trials, and a single stimulus can reduce pain scale scores by 50%, with efficacy maintained for 1-2 weeks. The plan is to build the headquarters and the first production line in the second quarter of this year, start production in the third quarter, initiate NMPA registration application by the end of the year, and achieve listing within 1-2 years.
The funds raised in this round will be mainly used for core technology breakthroughs, first product research and development, clinical registration promotion, and AI technology integration. The landing of this financing is not only a recognition of its technological leadership and clinical implementation capabilities by the capital market, but also confirms the global strategic value of the ultrasound brain computer interface track, which will help Gestalt Technology achieve “lane change and running” in this cutting-edge track and promote the high-quality development of China’s brain computer interface industry.
5ć PuNuo Zhiyao has completed an angel round financing of nearly 100 million yuan, using AI to break through protein interactions and accelerate pipeline clinical translation
On March 11th, PuNuoZhi Pharmaceutical (Suzhou) Biotechnology Co., Ltd., an innovative pharmaceutical company focusing on “difficult to achieve drug targets”, announced the completion of nearly 100 million yuan in angel round financing, led by HuaGai Capital and Boyuan Capital, with follow-up investment from Mint Angel Fund, marking the company’s official entry into a critical stage of clinical value realization.
This round of financing will focus on three core directions: accelerating the development of preclinical candidate molecules and IND applications for the STAT6 project, and exploring the translational value in the fields of inflammation and autoimmune diseases; Promote the IND application of PPI-101, the core pipeline of RBM39 molecular gel degrading agent. This new mechanism drug targets high clinical unmet need tumor species and has excellent tumor tissue penetration and killing ability; Simultaneously, rapidly optimize and iterate the protein-protein interaction (PPI) based AI drug development platform, empowering efficient and rational design of small molecule PPI inhibitors and degraders.
PuNuo Zhiyao takes PPI as the core entry point and deeply integrates AI technology to build a full chain drug design system with PPI as the starting point and drug properties as the endpoint. Relying on high-quality databases and innovative algorithms, it achieves intelligent molecular generation and precise prediction of complex drug properties, effectively overcomes single and difficult targets, and quickly generalizes to similar PPI families, efficiently expanding the high barrier pipeline matrix. The company team is composed of top scientists and senior industry experts, forming an efficient research and development loop of “wet dry combination”, and currently making rapid progress in research and development.
The investors highly recognize the company’s technological roadmap and clinical value. Huagai Capital pointed out that AI, as a core productivity tool deeply integrated into the entire R&D process, will play a disruptive role in molecular optimization and new structure discovery; Boyuan Capital emphasizes that PPI drug development is an important trend in innovative drugs, and the company’s AI platform helps discover differentiated molecules, optimistic about its long-term potential in combining industry and academia. This financing is an authoritative verification by the market of the technology platform and early pipeline quality of PuNuo Zhiyao. In the future, the company will be guided by unmet clinical needs, accelerate the entry of core pipelines into clinical practice, and strive to provide differentiated substantive treatment plans for patients, promoting the high-quality development of PPI-AI drug research and development in China.
About Us
MeritsIP: Your Global Intellectual Property Partner
At MeritsIP, we provide comprehensive IP services in biomedicine, medical devices, manufacturing, semiconductors, and AI. We support 200+ top clients globally with strategic, high-quality IP services.
Stay Connected
-
- Website: https://www.meritsipglobal.com
-
- LinkedIn: Follow us on LinkedIn
-
- Email: info@meritsip.com
Ā© 2025 MeritsIP. All Rights Reserved.
